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In India, quality surveillance for acute encephalitis syn-
drome (AES), including laboratory testing, is necessary for 
understanding the epidemiology and etiology of AES, plan-
ning interventions, and developing policy. We reviewed AES 
surveillance data for January 2011–June 2012 from Kushi-
nagar District, Uttar Pradesh, India. Data were cleaned, in-
cidence was determined, and demographic characteristics 
of cases and data quality were analyzed. A total of 812 AES 
case records were identified, of which 23% had illogical en-
tries. AES incidence was highest among boys <6 years of 
age, and cases peaked during monsoon season. Records 
for laboratory results (available for Japanese encephalitis 
but not AES) and vaccination history were largely incom-
plete, so inferences about the epidemiology and etiology 
of AES could not be made. The low-quality AES/Japanese 
encephalitis surveillance data in this area provide little evi-
dence to support development of prevention and control 
measures, estimate the effect of interventions, and avoid 
the waste of public health resources.
Acute encephalitis syndrome (AES) is a clinical condi-tion caused by infection with Japanese encephalitis 
virus (JEV) or other infectious and noninfectious causes. 
A confirmed etiology is generally not required for the 
clinical management of AES. Thus, surveillance for JEV 
infection in India has focused on identifying AES cases 
rather than JE cases; this approach is more feasible given 
the limitations of public health resources (1). However, 
identification of the etiologic agent is necessary for plan-
ning relevant interventions. The standard for determining 
the etiology of AES is examination of cerebrospinal fluid 
(CSF) during the acute phase of illness; pathogen-specific 
IgM capture ELISA or nucleic acid amplification tech-
niques are used to detect pathogens in the CSF. Serologic 
tests for pathogen-specific antibodies and virus detection 
in serum are also recommended. However, examination of 
CSF is preferred because serologic test results may indi-
cate the presence of antibodies in the serum, but the AES 
may have a cause different than the agent producing the 
detected antibodies (1–3).
A good quality surveillance system with laboratory 
support is essential for understanding the causes of AES 
and responding appropriately. Accordingly, the National 
Vector Borne Diseases Control Programme in New Del-
hi, India, has developed guidelines for AES surveillance 
that promote the need for a strong surveillance system as 
a critical component for any control activities. In these 
guidelines, the goals outlined for AES surveillance are 
to 1) assess and characterize the burden of JE, 2) detect 
early warning signals for an outbreak, 3) assess the ef-
fect of vaccination, and 4) guide future strategies (1). The 
National Vector Borne Diseases Control Programme has 
also implemented several measures to strengthen local 
health systems, including building on the capacity of the 
health workforce to provide better clinical management, 
extending referral diagnostic facilities by upgrading the 
existing Baba Raghav Das (BRD) Medical College facili-
ties and setting up a National Institute of Virology field 
unit; and establishing a dedicated surveillance unit in the 
Department of Preventive and Social Medicine at BRD 
Medical College to provide improved surveillance and 
outbreak responses (4).
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PERSPECTIVE
From the 1970s until around 2010, JEV infection was 
considered to be the leading cause of AES in the traditional 
JE belt of India, which includes Kushinagar District in the 
state of Uttar Pradesh (5–11). However, because of a large 
number of JE cases of unknown etiology, AES patterns 
alone have not suggested a clear picture of the epidemiol-
ogy of the disease. In recent years, despite of the introduc-
tion of a JE vaccine, an increased number of AES cases 
have been reported in India, including Uttar Pradesh, and 
the disease has spread to new districts, urban areas, and 
villages without pigs, which are not usually associated with 
JE transmission (12,13). Thus, the assertion that JEV is the 
leading cause of AES has been questioned, and other infec-
tious agents, such as enteroviruses, have been reported as 
a cause of AES in Uttar Pradesh and other parts of India 
(14–19). A substantial contributor to the ambiguity about 
the etiology of AES could be the fact that surveillance data 
for AES have not been analyzed to assess reasons for the 
increased cases and other reported causes. We examined 
the completeness and quality of AES surveillance data 
from Kushinagar District, an area where JEV is highly en-
demic. Herein, we discuss the ability to make inferences 
about AES epidemiology and etiology from these data and 
the implications of our findings for policy planning and 
program implementation.
Methods
Source of Surveillance Data
The sentinel site for JE surveillance in Kushinagar 
District is the district hospital. Using a standard format, 
the hospital reports all AES/JE cases that meet the standard 
World Health Organization case definition (3) to the district 
malaria officer; this officer then forwards compiled data to 
the state program officer for transmission to National Vec-
tor Borne Disease Control Programme (http://nvbdcp.gov.
in/Doc/AES%20guidelines.pdf). BRD Medical College in 
Gorakhpur, Uttar Pradesh, is a nearby regional field labo-
ratory of the Indian Council of Medical Research, which 
receives clinical samples from patients admitted to the dis-
trict hospital in Kushinagar and completes most laboratory 
testing for JEV infections. In addition, BRD Medical Col-
lege serves as a tertiary care center for patients who directly 
seek medical care or who are referred from nearby districts, 
including Kushinagar. A line list with laboratory results of 
these patients is reported by BRD Medical College to the 
district malaria officer in Kushinagar for submission to 
state program officers.
In July 2012, we obtained the AES line lists data for 
January 2011–June 2012 that were submitted by BRD 
Medical College to Kushinagar District Headquarters in 
Padrauna. The list was originally to be used to identify 
blocks in Kushinagar District with high, medium, and 
low numbers of AES cases so that sites could be select-
ed for a larger study of the drivers of JEV transmission. 
Cases recorded in the line lists represented case-patients 
from Kushinagar District who were 1) admitted directly 
to BRD Medical College, 2) referred to BRD Medical 
College by the district hospital in Padrauna, and 3) admit-
ted to the district hospital in Padrauna but had serum sam-
ples referred to BRD Medical College because no diagnos-
tic kits were available and laboratory testing was limited 
at the district hospital. An individual AES patient tracking 
system does not exist in the state of Uttar Pradesh, so pa-
tients treated in the private sector or at the district hospital 
in Gorakhpur were not included in the surveillance lists.
Preparation of Surveillance Database for Analysis
Individual identifiers for the case-patients were re-
moved from the line lists to ensure confidentiality. Data 
were cleaned (i.e., extraneous data were removed) in mul-
tiple steps, resulting in 4 changes being made to the AES 
line lists. First, the spelling of residential localities (block, 
village, or police station) were matched and standardized 
to result in a list of 32 residential areas. Residential areas 
were then categorized and combined by block (14 blocks 
in Kushinagar). Modifications were validated by cross-
checking with village population lists provided by Sav-
era, a local nongovernmental organization. Second, all 
age values were standardized to a uniform decimal sys-
tem (e.g., 1 year and 6 months was changed to 1.5 years, 
and 8 months was changed to 0.67 year). Third, the dates 
of symptom onset, hospital admission, sample collection, 
and outcome (i.e., discharged, left against medical advice, 
or death) were standardized to 1 format. In the original 
list, dates were variously coded by using different nota-
tions (e.g., 4 March 2011 was mentioned within the same 
row as both 04/03/11 and 03/04/11). Assuming that the 
case data were entered in chronological order, we stan-
dardized dates by using, as a cue, the dates of the preced-
ing and following AES cases. Fourth, case-patients who 
died, were absent, or left against medical advice were 
considered to have been discharged.
Data Analysis
Cleaned data were imported into SAS version 9.2.2 
(SAS Institute, Inc., Cary, NC, USA) for analysis. AES 
cases were plotted by week and month by using the re-
corded dates of symptom onset. We tabulated demographic 
characteristics of AES case-patients for 2011 and 2012 
and stratified case-patients by block, vaccination status, 
laboratory test result for JEV infection, and clinical out-
come. Incidence for 2011 was calculated by using popula-
tion denominators from the 2011 Census of India (20). We 
calculated incidence overall, by sex, and for children 0–6 
years of age by using the age stratification available in the 
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district-level census data. We estimated the incidence for 
each block by using block-specific population denomina-
tors projected with the decadal growth rate from the 2001 
Census of India (20). Crude incidence rate ratios were esti-
mated with Wald-based CIs.
We also determined the median number of days be-
tween key points in AES disease progression and diagnosis: 
time between onset of symptoms and hospital admission, 
onset of symptoms and serum sample collection, hospital 
admission and serum sample collection, and hospital ad-
mission and discharge or death. Using previously described 
methods (21), we evaluated the quality of the surveillance 
data by assessing the amount of data cleaning required, 
the proportion of missing or incomplete values in line list 
fields, and inconsistencies in dates recorded for key points 
in AES disease progression and diagnosis.
Results
AES Epidemiology
In 2011, a total of 721 AES cases from Kushinagar 
District were identified through BRD Medical College; in 
2012 (January–June), 91 cases were identified. Using the 
cleaned line lists, we determined the weekly number of 
AES cases reported during January 2011–June 2012 (Fig-
ure 1). Cases peaked during August–October 2011; >150 
cases were identified in each of these 3 months. This sea-
sonal trend corresponds with an expected increase in cases 
during the monsoon season, when transmission of both wa-
terborne and vector-borne diseases increases (vector den-
sity is at its maximum).
In 2011 and 2012, most case-patients were male 
(57.4% and 59.3%, respectively) (Table 1). In 2011, al-
most half of the AES cases were in children <5 years of 
age (44.7%); the distribution of cases by age group was not 
substantially different in 2012. The case-fatality rate was 
18.0% in 2011 and 19.8% in 2012.
Using 2011 population data (20), we estimated that 
there were 20.2 AES cases/100,000 population in Kushi-
nagar District in 2011 (Table 2). The incidence was higher 
among male residents than female residents (incidence rate 
ratio 1.29, 95% CI 1.11–1.49), and it was highest among 
children 0–6 years of age. The crude incidence rate ratio, 
comparing case-patients 0–6 years of age with those >6 
years of age, was 7.97 (95% CI 6.87–9.25). Boys 0–6 years 
of age were at highest risk for AES. The incidence among 
0- to 6-year-old boys was almost 50% greater than that 
among girls of the same age.
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Figure 1. Weekly number of acute encephalitis syndrome cases, by month, in Kushinagar District, Uttar Pradesh State, India, 2011–2012. 
Numbers are based on data obtained from Baba Raghav Das Medical College, Gorakhpur, Uttar Pradesh, India. 
 
Table 1. Characteristics of case-patients with acute encephalitis 
syndrome, Kushinagar District, Uttar Pradesh, India, 2011–2012* 
Characteristic 
No. (%) cases 
2011, n = 721 2012, n = 91 
Age, y   
 0–4 322 (44.7) 36 (39.6) 
 5–9 205 (28.4) 22 (24.2) 
 10–14 83 (11.5) 12 (13.2) 
 15 111 (15.4) 21 (23.1) 
Sex   
 M 414 (57.4) 54 (59.3) 
 F 307 (42.6) 37 (40.7) 
Religion   
 Hindu 632 (87.7) 80 (87.9) 
 Muslim 89 (12.3) 11 (12.1) 
Vaccinated against JEV   
 Yes 3 (0.4) 0 
 No 116 (16.1) 0 
 Unknown 602 (83.5) 91 (100) 
Outcome   
 Died 130 (18.0) 18 (19.8) 
 Absent 18 (2.5) 0 
 LAMA 16 (2.2) 0 
 Discharged 557 (77.3) 73 (80.2) 
Result for JEV laboratory test   
 Positive 3 (0.4) 0 
 Negative 128 (17.8) 0 
 Awaited† 590 (81.8) 91 (100) 
*Based on data obtained from Baba Raghav Das Medical College, 
Gorakhpur, Uttar Pradesh, India. JEV, Japanese encephalitis virus; LAMA, 
left against medical advice. 
†Clinical samples awaiting laboratory test results. 
 
PERSPECTIVE
The weekly numbers of AES cases, classified by JE 
IgM laboratory result (positive, negative, awaiting deter-
mination), is shown in Figure 2. Only 3 (4.2%) cases of 
JEV infection were identified in 2011: two cases were 
in 55-year-old men, 1 of whom died, and 1 case was in 
a 14-year-old girl. Vaccination status was reported for 
119 case-patients, of whom 3 (2.6%) had been vaccinated. 
The case-patients who had received vaccine were boys 
6, 7, and 8 years of age; they began experiencing symp-
toms in July 2011 and were discharged within 3 weeks 
of hospital admission. None of the 3 JE case-patients had 
been vaccinated.
Quality of Surveillance Data 
During data cleaning, we modified 25% of the 2011 
and 5% of the 2012 line list values for residential locality, 
age, and date parameters (Table 3). Nearly one fifth of the 
age data and more than one fourth of the dates were edited. 
For 3.2% and 13.2% of cases in 2011 and 2012, respective-
ly, the block name could not be determined from the resi-
dential locality provided and was marked as “unknown” 
because the village or police station name was not found or 
was present in multiple blocks. In addition, several fields in 
the database were incomplete. As of July 2012, laboratory 
results for JEV infection were still classified as “awaited” 
(i.e., awaiting determination) in the line lists for 82% (590) 
of the 721 cases in 2011 and for all 91 cases in 2012 (Table 
1). The line lists indicated the date of sample collection, but 
the type of sample collected (CSF and/or serum) and the 
laboratory test used (IgM ELISA, PCR, and/or cell culture) 
were not recorded for any of the case-patients. Most sam-
ples submitted after July 2011 were still awaiting labora-
tory results at the time of our study (Figure 2). In addition, 
for 602 (83.5%) of the 721 case-patients in 2011 and all 91 
case-patients in 2012, JEV vaccination status was marked 
as “unknown” in the line lists (Table 1).
Key epidemiologic and programmatic indicators, such 
as the time between key points in AES disease progression 
and diagnosis, varied widely among case-patients (Table 
4). In some instances, the dates were illogical (e.g., dates of 
symptom onset and sample collection following and pre-
ceding the dates of hospital admission, respectively). It was 
not possible to rectify these inconsistencies on the basis of 
the available data. In addition, the range of values was of-
ten large. For example, median time from onset of symp-
toms to hospital admission was 4 days in 2012, but some 
patients were admitted >2 months after symptom onset. 
Because AES is an acute syndrome, a long interval is not 
expected between symptoms and may indicate reporting of 
unrelated symptoms or misclassification of AES.
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Table 2. Incidence of acute encephalitis syndrome, Kushinagar District, Uttar Pradesh, India, 2011–2012* 
Age, sex of population 2011 population† No. cases Incidence‡ Incidence rate ratio (95% CI) 
All ages 3,560,830 721 20.2  
 M 1,821,242 414 22.7 1.29 (1.11–1.49) 
 F 1,739,588 307 17.6 1.0 
0–6 y 551,467 428 77.6  
 M 287,672 260 90.4 1.42 (1.17–1.72) 
 F 263,795 168 63.7 1.0 
*Based on data obtained from Baba Raghav Das Medical College, Gorakhpur, Uttar Pradesh, India. 
†From 2011 Census of India (20). 
‡Per 100,000 population. 
 
Figure 2. Weekly number of acute 
encephalitis syndrome cases, by 
month, in Kushinagar District, 
Uttar Pradesh State, India, 
2011–2012. Numbers represent 
results of laboratory testing for 
Japanese encephalitis and are 
based on data from Baba Raghav 
Das Medical College, Gorakhpur, 
India. In the key, “awaited” refers 
to samples that were awaiting 
laboratory test results.
 Acute Encephalitis Syndrome Surveillance, India
Discussion
Despite the introduction of JE vaccine, an increased 
number of AES cases have been reported in Kushinagar 
District in recent years, and AES has been reported in 
areas not previously associated with the disease (12,13). 
Because of this apparently changing epidemiology of 
AES/JE in Kushinagar District, the importance of qual-
ity surveillance for guiding local and stratified caseload 
predictions for patient management and decision-making 
at policy and program levels cannot be overemphasized. 
However, our analyses show that despite recent attention 
regarding AES and public health interventions, constraints 
imposed by the district’s surveillance capacity hinder pa-
tient management, policy decisions, and implementation 
of prevention and control measures. The surveillance 
line list from BRD Medical College is representative 
of the district data on AES/JE (district malaria officer, 
pers. comm.). However, the current surveillance system 
captures only data for case-patients/samples that have 
been admitted/referred to BRD Medical College; thus, 
AES patients from Kushinagar District who seek medi-
cal care in the private sector are not represented in the 
surveillance data.
It seems that the surveillance database is not currently 
used for analysis at the district level; instead, the database is 
maintained only for administrative purposes, which include 
reporting to the State Directorate. However, the number of 
modifications that we had to make to the AES line lists for 
our analyses indicates that the quality of data collection is 
poor. We corrected some errors by making comparisons 
with other fields in the database, but other entries remain 
illogical (e.g., dates of hospital admission that proceed the 
dates of symptoms onset). Despite our thorough review and 
use of standardized protocol for cleaning the line lists, the 
results presented here should be viewed with regard to the 
inconsistencies in the original surveillance data. Regardless 
of the practical difficulties in coordination, collation, re-
cording, and reporting of data, the high level of incomplete 
records, especially for JEV vaccination status and labora-
tory result, suggests a lack of initiative by data collectors to 
record complete and accurate information.
Current surveillance data provide little credible infor-
mation to guide program planning and policy making for 
AES/JE in Kushinagar District. We could not determine if 
JE is etiologically responsible for AES in this area because 
reporting for JE laboratory testing was vague and incom-
plete. In addition, it is likely that only serum samples were 
collected to determine if AES was caused by JEV infection 
because the sampling procedure for serum is simpler than 
that for CSF. However, serum is a suboptimal sample for 
determining the cause of AES. Many JE infections are as-
ymptomatic, so AES may be caused by an agent other than 
JEV even if JEV–specific IgM is present in the serum (2,3). 
In addition, a live, attenuated JEV vaccine is used in India, 
so the presence of JEV IgM in serum may be the effect of 
previous vaccination. CSF is preferred over serum samples 
for JEV testing because the presence of JE antibody in CSF 
provides a definitive diagnosis of JEV infection. A record 
of the type of sample collected is also essential for assess-
ing the diagnostic yield of the sample and determining 
whether the sample was collected at the appropriate time 
after symptom onset (2). This need for a complex diagnos-
tic process may have contributed to the incompleteness of 
laboratory results.
Regardless of the type of sample collected, the record-
ing of JEV laboratory test results was inconsistent during 
the latter half of 2011 and nonexistent during 2012, despite 
collection of clinical samples soon after hospital admis-
sion. It is unknown whether the delays were caused by 
laboratory constraints or miscommunication in reporting 
the results. However, lack of timeliness in reporting sur-
veillance data hinders its utility for guiding interventions 
and responding to outbreaks. JEV laboratory test results 
were available only during the low-transmission period, 
thus excluding any analysis for peak-transmission periods. 
JEV vaccination has been variously reported at 52% (22) to 
>95% (district health authorities, pers. comm.). We could 
not use the current surveillance data to estimate or validate 
the reported coverage figures because most vaccination his-
tories were unknown.
Even basic epidemiologic analyses of demographic 
characteristics cannot be confidently interpreted as true or 
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Table 3. Values modified in line lists of case-patient data used in a study of acute encephalitis syndrome, Kushinagar District, Uttar 
Pradesh, India, 2011–2012* 
Case-patient value 
No. (%) modified 
2011, n = 721 2012, n = 91 Combined, n = 812 
Name of block of residence 192 (26.6) 2 (2.2) 194 (23.9) 
Age 128 (17.8) 18 (19.8) 146 (18.0) 
Date of symptom onset  221 (30.7) 4 (4.4) 225 (27.7) 
Date of fever onset 213 (29.5) 4 (4.4) 217 (26.7) 
Date of admission 193 (26.8) 2 (2.2) 195 (24.0) 
Date of sample collection 186 (25.8) 1 (1.1) 187 (23.0) 
Out come 139 (19.3) 2 (2.2) 141 (17.4 
All fields 183 (25.4) 33 (36.3) 216 (26.6) 




simply as the results of poor data collection. In the absence 
of reliable data, technical discussions have been overshad-
owed by shifting hypotheses about the etiology and epide-
miology of AES, but these discussions are without a strong 
evidence base. For example, recent debates centered on the 
role of pigs in JEV transmission, yet the debates lacked 
relevant data about pigs in the area. In a similar manner, 
focus has shifted to waterborne causes of encephalitis, even 
though studies that have identified enteroviruses in patient 
samples have not concluded that waterborne pathogens 
are the main cause of AES incidence (14–16,18). These 
studies used different sampling methods and had differ-
ent results, so the relative contributions of waterborne and 
vector-borne agents to AES cases in Kushinagar District 
remain unknown. Interventions cannot be planned when, 
depending on the etiology of AES, strategies as diverse as 
strengthening vaccination to improving water quality and 
sanitation may be appropriate. Quality surveillance data, 
including laboratory results and vaccination history, would 
resolve the inconsistencies between studies and inform in-
tervention strategies.
Conclusion
The current AES/JE surveillance system has a compli-
cated specimen referral and reporting system at the district 
level, and the available line lists suggest that data are of 
low quality. Without evidence to estimate the effect of in-
terventions, AES prevention and control measures may be 
ineffective and public health resources may be wasted. In 
2011, AES and JE were highlighted in the national media, 
leading to a declaration for several policy initiatives, in-
cluding formation of a multisectorial and interministerial 
National Encephalitis Control Programme (23). Despite the 
high profile of AES, the importance of surveillance data for 
guiding these initiatives has not been realized or translated 
to action. Gaps in surveillance capacity that were identified 
in this study indicate the need for a systematic evaluation 
of the AES/JE surveillance system in Kushinagar District 
and constitute key lessons that need to be incorporated as 
strategic planning is undertaken for this new initiative.
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